Date | Price Target | Rating | Analyst |
---|---|---|---|
8/5/2024 | $472.00 → $509.00 | Overweight → Equal Weight | Barclays |
6/27/2024 | $545.00 | Buy | Redburn Atlantic |
4/11/2024 | $438.00 | In-line → Outperform | Evercore ISI |
2/15/2024 | $515.00 | Outperform | Wolfe Research |
2/6/2024 | $436.00 → $438.00 | Outperform → In-line | Evercore ISI |
2/2/2024 | Outperform → Mkt Perform | Bernstein | |
1/31/2024 | $325.00 | Neutral → Underperform | Robert W. Baird |
1/31/2024 | Buy → Hold | Maxim Group |
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced management participation in two upcoming investor conferences. Dr. Reshma Kewalramani, Chief Executive Officer and President, and Charles Wagner, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, 2024 at 11:30 a.m. ET. Susie Lisa, Senior Vice President of Investor Relations and Manisha Pai, Executive Director of Investor Relations, will participate in a fireside chat at the Cantor Global Healthcare Conference on Tuesday, September 17, 2024 at 9:10 a.m. ET. A live webcast of management's rem
- Eligible transfusion-dependent beta thalassemia (TDT) patients in England will be able to access the therapy from today - - CASGEVY is one of the first medicines funded by NHS England's Innovative Medicines Fund - Vertex Pharmaceuticals (NASDAQ:VRTX) announced today a reimbursement agreement with NHS England for eligible transfusion-dependent beta thalassemia (TDT) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY™ (exagamglogene autotemcel), from today. The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guidance recommending CASGEVY's use in the NHS. The United Kingdom (U.K.) Medicines and Healthcare pro
— Product revenue of $2.65 billion, a 6% increase compared to Q2 2023 — — Company raises full year product revenue guidance to $10.65 to $10.85 billion — — FDA accepted NDA for vanzacaftor triple in CF with Priority Review and PDUFA target action date of January 2, 2025; additionally, MAA submissions validated in EU and U.K. — — FDA accepted NDA for suzetrigine (VX-548) for moderate-to-severe acute pain with Priority Review and PDUFA target action date of January 30, 2025 — — Advancing broad and deep clinical pipeline with multiple milestones expected in H2:24 — Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today reported consolidated financial results for the second quarter e
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Nancy Thornberry has been appointed to its Board of Directors as an independent director. Ms. Thornberry has more than 35 years of experience in the pharmaceutical and biotech industries, spanning drug discovery, development and commercialization. She founded and served as Chief Executive Officer of Kallyope until 2021 and remains on its Board of Directors and is Chair of Research & Development. Prior to joining Kallyope, Ms. Thornberry spent more than 30 years at Merck & Co., Inc., most recently as Senior Vice President and Global Franchise Head, Diabetes and Endocrinology, with responsibility for discovery and clinical
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Michel Lagarde has been appointed to its Board of Directors as an independent director. Mr. Lagarde is a senior health care and business leader with global expertise, currently serving as Chief Operating Officer and Executive Vice President of Thermo Fisher Scientific Inc. Prior to Thermo Fisher, Mr. Lagarde served as President and Chief Operating Officer of Patheon, a contract manufacturer to the biopharma industry, and as a Managing Director at JLL Partners, a private equity firm investing in health care services. "We are delighted to have Michel join the Vertex Board. His deep experience across numerous segments of
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that E. Morrey Atkinson, Ph.D., has been appointed Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations, effective immediately. Dr. Atkinson has served as Senior Vice President of Global Commercial Manufacturing and Supply Chain since July 2020. This new role and function unifies responsibility for small molecule, cell and gene therapies across preclinical, clinical and commercial biopharmaceutical sciences, manufacturing operations and global supply chain. "Over the last three years, Morrey has played a vital role in building out our commercial manufa
144 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)
8-K - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)
10-Q - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer)
4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)
4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)
4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)
SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)
SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)
SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)
For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali
Submission status for VERTEX PHARMS INC's drug TRIKAFTA (COPACKAGED) (SUPPL-2) with active ingredient ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR has changed to 'Approval' on 08/03/2023. Application Category: NDA, Application Number: 217660, Application Classification: Labeling
Submission status for VERTEX PHARMS INC's drug TRIKAFTA (COPACKAGED) (SUPPL-11) with active ingredient ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR has changed to 'Approval' on 08/03/2023. Application Category: NDA, Application Number: 212273, Application Classification: Labeling
Barclays downgraded Vertex Pharma from Overweight to Equal Weight and set a new price target of $509.00 from $472.00 previously
Redburn Atlantic initiated coverage of Vertex Pharma with a rating of Buy and set a new price target of $545.00
Evercore ISI upgraded Vertex Pharma from In-line to Outperform and set a new price target of $438.00
TD Cowen analyst Phil Nadeau maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $450 to $500.
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 11.09% on an annualized basis producing an average annual return of 24.11%. Currently, Vertex Pharmaceuticals has a market capitalization of $126.33 billion. Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 5 years ago, it would be worth $293.44 today based on a price of $489.55 for VRTX at the time of writing. Vertex Pharmaceuticals's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Be
Cantor Fitzgerald analyst Olivia Brayer maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $440 to $480.
— Product revenue of $2.65 billion, a 6% increase compared to Q2 2023 — — Company raises full year product revenue guidance to $10.65 to $10.85 billion — — FDA accepted NDA for vanzacaftor triple in CF with Priority Review and PDUFA target action date of January 2, 2025; additionally, MAA submissions validated in EU and U.K. — — FDA accepted NDA for suzetrigine (VX-548) for moderate-to-severe acute pain with Priority Review and PDUFA target action date of January 30, 2025 — — Advancing broad and deep clinical pipeline with multiple milestones expected in H2:24 — Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today reported consolidated financial results for the second quarter e
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its second quarter 2024 financial results on Thursday, August 1, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals Second Quarter 2024 Earnings Call." The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived
— Product revenue of $2.69 billion, a 13% increase compared to Q1 2023; reiterated full year 2024 financial guidance, including product revenue guidance of $10.55 to $10.75 billion — — Submitted NDA and MAA filings for vanzacaftor triple in CF to FDA and EMA, respectively — — Initiated rolling NDA submission for suzetrigine (VX-548) in moderate-to-severe acute pain and on track to complete this quarter — — Entered into agreement to acquire Alpine Immune Sciences, including povetacicept, a Phase 3-ready asset in IgA nephropathy and potential pipeline-in-a-product — Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today reported consolidated financial results for the first quarter en